Avid Bioservices Inc (CDMO)

[sunstar]

Avastin is approved only for colon/rectal cancer. It is expected to earn $1.6 billion in 2006.

The bavituximab multiplier:

Bavituximab works on all solid tumors. Bavi is now being tested with three different chemotherapies on any cancers that these chemo’s are used with currently. That will lead into a phase two study that will see bavi being used against many types of solid tumors.

Three chemo’s with a number of cancer types each, multiplies out into numerous cancer indications for bavituximab. How many types of tumors? Six?? Twelve?? Twenty??...More??

Multiplied by, say, $1.6 billion each…….$10 to $32 billion??...More??

Then it works really well with radiation too; a few billion more??

We’re just talking cancer here too.

The potential of bavituximab as a cancer treatment is just enormous.

sunstar